Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01WPJ
|
|||
| Former ID |
DNC002888
|
|||
| Drug Name |
Duroquinone
|
|||
| Synonyms |
Duroquinone; 527-17-3; Tetramethyl-1,4-benzoquinone; Tetramethyl-p-benzoquinone; Tetramethylquinone; 2,3,5,6-Tetramethyl-1,4-benzoquinone; 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione; Tetramethyl-p-quinone; 2,3,5,6-Tetramethylbenzoquinone; p-Benzoquinone, tetramethyl-; p-Benzoquinone, 2,3,5,6-tetramethyl-; 2,3,5,6-Tetramethyl-p-benzoquinone; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetramethyl-; NSC 2068; CCRIS 2989; p-Benzoquinone, tetramethyl-, semiquinone; UNII-X0Q8791R69; EINECS 208-409-8
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12O2
|
|||
| Canonical SMILES |
CC1=C(C(=O)C(=C(C1=O)C)C)C
|
|||
| InChI |
1S/C10H12O2/c1-5-6(2)10(12)8(4)7(3)9(5)11/h1-4H3
|
|||
| InChIKey |
WAMKWBHYPYBEJY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 527-17-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
68762, 588832, 607328, 3133144, 4688082, 7887174, 8191960, 10525354, 14992389, 24893666, 25621878, 26697285, 43124839, 46507523, 49957345, 50786779, 57316781, 57394764, 66570101, 81065524, 85085757, 85247613, 87576545, 88822951, 92264459, 103108994, 103397113, 104341602, 109450941, 117398521, 125352204, 126546503, 129553590, 135150721, 135567500, 136368362, 137010593, 142338139, 144048682, 160799026, 160965151, 162181252, 162293490, 162864659, 163420633, 164109690, 164809599, 166240490, 172874384, 179093910
|
|||
| ChEBI ID |
CHEBI:42023
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Quinone reductase 1 (NQO1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Ubiquinone and other terpenoid-quinone biosynthesis | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Pathwhiz Pathway | Vitamin K Metabolism | |||
| Pathway Interaction Database | Validated transcriptional targets of TAp63 isoforms | |||
| WikiPathways | Estrogen metabolism | |||
| Oxidative Stress | ||||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
| Metabolism of amino acids and derivatives | ||||
| Aryl Hydrocarbon Receptor | ||||
| Dopamine metabolism | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.